SeekIn is able to launch its LeukoPrint molecular karyotyping check in European markets after receiving CE Mark approval.
The brand new package, meant for the analysis of leukemias, was designed to establish copy quantity aberration (CNA) patterns in leukemia sufferers based mostly on floor entire genome sequencing (sWGS).
It will probably additionally help hematologists in analysis and prognostic stratification in accordance with the rules of European Leukemia Internet (ELN), Revised Worldwide Prognostic Scoring System (IPSS-R) or Revised Worldwide Staging System (R-ISS).
Leukemias are a group of malignant issues of the blood and bone marrow that may happen at any age.
Moreover, LeukoPrint is appropriate for a lot of different types of hematological malignancies, equivalent to a number of myeloma.
SeekIn Founder and CEO Mao Mao stated, “With the appearance of latest DNA sequencing applied sciences, next-generation sequencing (NGS)-based genetic testing has been applied as a protocol routine for most cancers analysis, threat stratification and evaluation of response to therapy.
“LeukoPrint gives a cheap and simplified technique for fast and correct ANC profiling in sufferers with leukemia. He used a standardized protocol, which will be simply prolonged to scientific laboratories around the globe.
“With the benefit of detecting NACs from brief DNA fragments, integrating with routine diagnostic strategies, LeukoPrint can profit from standard cytogenetics by enhancing diagnostic yield.”
The corporate moreover expects to obtain regulatory approvals in different territories, equivalent to China.
He says the brand new check provides excessive accuracy and sensitivity and will help sufferers keep away from the ache of getting to provide a number of bone marrow samples.
LeukoPrint additionally makes molecular subtyping, prognostic stratification, and therapy response monitoring correct and complete.